What is the role of teriflunomide and dimethyl fumarate in the treatment of pediatric multiple sclerosis (MS)?

Updated: Jan 30, 2019
  • Author: Alice K Rutatangwa, DO, MSc; Chief Editor: Amy Kao, MD  more...
  • Print

Safety and efficacy of teriflunomide and dimethyl fumarate are not established in pediatric patients with MS. Off-label use of these medications should be pursued cautiously given the known adverse effects in adults. Teriflunomide labeling includes a boxed warning regarding severe liver injury and teratogenicity. Dimethyl fumarate cautions include lymphopenia, flushing, PML, angioedema, and liver injury.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!